Literature DB >> 16893403

Erythropoietin resistance in the treatment of the anemia of chronic renal failure.

Anumeet Priyadarshi1, Joseph I Shapiro.   

Abstract

Resistance to erythropoietin therapy is a common complication of the modern management of anemia in chronic kidney disease. Iron deficiency, deficiency of other nutrients, toxins, infections, and inadequate dialysis account for the vast majority of episodes of such resistance.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16893403     DOI： 10.1111/j.1525-139X.2006.00172.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN： 0894-0959            Impact factor:   3.455


  12 in total

Review 1.  Inflammation and L-carnitine therapy in hemodialysis patients: a review.

Authors:  Saman Khalatbari-Soltani; Hadi Tabibi
Journal:  Clin Exp Nephrol       Date:  2014-12-02       Impact factor: 2.801

2.  Erythropoietin and Soluble Erythropoietin Receptor: A Role for Maternal Vascular Adaptation to High-Altitude Pregnancy.

Authors:  Gabriel H Wolfson; Enrique Vargas; Vaughn A Browne; Lorna G Moore; Colleen G Julian
Journal:  J Clin Endocrinol Metab       Date:  2017-01-01       Impact factor: 5.958

3.  Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.

Authors:  Rachel Gavish; Salmas Watad; Nathalie Ben-Califa; Ori Jacob Goldberg; Orly Haskin; Miriam Davidovits; Gili Koren; Yafa Falush; Drorit Neumann; Irit Krause
Journal:  Pediatr Nephrol       Date:  2018-07-20       Impact factor: 3.714

4.  Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis.

Authors:  Kyung Hwan Jeong; Tae Won Lee; Chun Gyoo Ihm; Sang Ho Lee; Ju Young Moon
Journal:  Exp Mol Med       Date:  2008-04-30       Impact factor: 8.718

Review 5.  Erythropoietin pharmacology.

Authors:  J M Jurado García; E Torres Sánchez; D Olmos Hidalgo; E Alba Conejo
Journal:  Clin Transl Oncol       Date:  2007-11       Impact factor: 3.405

6.  Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Pablo E Pergola; Matt Devalaraja; Steven Fishbane; Michel Chonchol; Vandana S Mathur; Mark T Smith; Larry Lo; Kurt Herzog; Rahul Kakkar; Michael H Davidson
Journal:  J Am Soc Nephrol       Date:  2020-12-03       Impact factor: 10.121

Review 7.  Applications of Metals for Bone Regeneration.

Authors:  Kristina Glenske; Phil Donkiewicz; Alexander Köwitsch; Nada Milosevic-Oljaca; Patrick Rider; Sven Rofall; Jörg Franke; Ole Jung; Ralf Smeets; Reinhard Schnettler; Sabine Wenisch; Mike Barbeck
Journal:  Int J Mol Sci       Date:  2018-03-12       Impact factor: 5.923

8.  Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.

Authors:  Eliyahu V Khankin; Walter P Mutter; Hector Tamez; Hai-Tao Yuan; S Ananth Karumanchi; Ravi Thadhani
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

9.  Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD.

Authors:  Christine Pietrement; Laëtitia Gorisse; Stéphane Jaisson; Philippe Gillery
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

10.  Do diabetic dialysis patients require more or less of erythropoietin?

Authors:  Ahmad Mitwalli; Abdulkareem Alsuwaida; Jamal Al Wakeel; Saira Usama; Nouf Zainalddain; Mohammed Al Ghonaim; Durdana Hammad
Journal:  Ann Saudi Med       Date:  2013 Sep-Oct       Impact factor: 1.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.